Last reviewed · How we verify
Re-induction Therapy
Re-induction therapy refers to a treatment protocol that re-administers chemotherapy or targeted agents to patients who have relapsed or achieved remission, aiming to restore disease control in hematologic malignancies.
Re-induction therapy refers to a treatment protocol that re-administers chemotherapy or targeted agents to patients who have relapsed or achieved remission, aiming to restore disease control in hematologic malignancies. Used for Acute leukemia (relapsed or refractory disease), Blood and hematologic malignancies requiring re-treatment.
At a glance
| Generic name | Re-induction Therapy |
|---|---|
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Re-induction therapy is a clinical strategy rather than a single drug entity, typically used in blood cancers such as acute leukemias. It involves re-treating patients with chemotherapy regimens (often similar to initial induction therapy) after relapse or to consolidate remission. The approach leverages chemosensitivity to re-establish disease control in patients whose malignant cells may have become quiescent or partially resistant.
Approved indications
- Acute leukemia (relapsed or refractory disease)
- Blood and hematologic malignancies requiring re-treatment
Common side effects
- Myelosuppression
- Infection
- Mucositis
- Hepatotoxicity
- Cardiotoxicity
Key clinical trials
- Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer (PHASE2)
- Non-Invasive Programmed Stimulation (NIPS) to Guide the Subsequent VT Therapeutic Strategies (NA)
- Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer (PHASE2)
- Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia (PHASE1)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML (PHASE3)
- Upfront Neck Dissection Before Radiotherapy in Stage N3 Nasopharyngeal Carcinoma: A Retrospective Study
- Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Re-induction Therapy CI brief — competitive landscape report
- Re-induction Therapy updates RSS · CI watch RSS
- Institute of Hematology & Blood Diseases Hospital, China portfolio CI